My watch list  

Evotec jump-starts biologics with acquisition of Just Biotherapeutics


Evotec SE announced the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”), for up to $ 90 m including potential performance-based earn-out components expected within the next three years. Just.Bio is a unique technology company that integrates highly synergistic scientific expertise and ML driven technologies for design, development, and manufacturing of biologics. Founded only in 2014/15, Just.Bio has approx. 90 employees, mainly scientists, all working at a state-of-the-art discovery, development and manufacturing facility in Seattle, WA, USA. The acquisition is expected to close in the second quarter 2019.

Opens new growth opportunites as Evotec diversifies into biologics

The acquisition of Just.Bio will add considerable business opportunities for further acceleration of Evotec’s long-term strategy to be the industry partner of choice for external end-to-end innovation. Evotec’s drug discovery and development value proposition today is to offer the highest quality integrated services mainly in the field of small molecules. The acquisition grows Evotec’s business into a comprehensive offering including biologics in therapeutic areas such as oncology, CNS, pain, inflammation, metabolics, and infectious diseases. Like Evotec in small molecules, Just.Bio is defined by its excellence in science and technology, defined outcomes, smart and highly efficient solutions for developing and manufacturing of biologics at highest standards, thus making an excellent fit.

Just.Bio’s capabilities and expertise comprise an in-house, integrated technology platform, J.DESIGN, enabling smart and efficient biologics’ drug development from design and lead optimisation to manufacturing:

  • J.MDTM is a technology-based process development tool using Abacus™ as machine learning-based computer-aided design tool to predict and select optimial molecules for further development
  • JP3® includes lab and computational tools for rapid development of a high-yielding manufacturing process along with a cGMP early clinical manufacturing facility
  • Significant further potential lies in the company’s J.POD® technology for flexible and modular larger scale manufacturing of clinical and commercial stage biologics

Transaction structure reflects value potential

During recent years, Just.Bio has been able to attract a diversified customer portfolio resulting in strong financial growth. With reported 2018 revenues of approx. € 20 m, Just.Bio was able to achieve revenue growth rates that are above the general market growth. Evotec will pay a total consideration of up to $ 90 m (approx. € 81 m; €/$ fx rate of 1.117) including potential earn outs in the next three years. The initial consideration upon closing is $ 60 m1) (approx. € 54 m; €/$ fx rate of 1.117). The acquisition of 100% of the issued and outstanding equity interests of the company will be paid in cash to a syndicate of institutional investors of ARCH Venture Partners, Merck & Co., Lilly Asia Ventures and the Bill & Melinda Gates Foundation. The acquisition will add to Evotec’s revenue growth and will strengthen Evotec’s overall strategic plan. The potential guidance update will be given latest upon reporting of half-year 2019 figures. Just.Bio will be financially fully consolidated under the Evotec Group.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: “We are excited about the acquisition and warmly welcome Just.Bio’s expert team as a new part of the Evotec family and also welcome Dr Jim Thomas in his new management role EVP, Global Head, Biotherapeutics, President US Operations. Broadening our platform into biologics has always been key to our strategy. With this acquisition we finally found the perfect match to complement our leadership in small molecules.”

Dr James Thomas, Chief Executive Officer of Just.Bio, commented: “Combining Just.Bio with Evotec creates a technological powerhouse that will fuel our long-term mission to make important biologics accessible to patients worldwide. We are thrilled to be part of the Evotec family.”

Facts, background information, dossiers
  • acquisitions
  • biologics
More about Evotec
  • News

    New IMI project “GNA NOW” kicks off its battle against antimicrobial resistance

    Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel antibacterial agents: Gram-Negative Antibacterials NOW (“GNA NOW”). The new GNA NOW project, led by Evotec SE, managed by Lygature and funded by the Innovative Medicines Initiative (IMI), wil ... more

    Evotec expands its iPSC discovery platform

    Evotec SE announced that the Company has acquired assets from the stem cell specialist Ncardia AG to advance Evotec’s iPSC platform. The acquired assets include intellectual property relevant for iPSC-based phenotypic drug discovery, an existing cellular product business around iPSC-derived ... more

    Evotec and venture capital consortium form "Breakpoint Therapeutics GmbH"

    Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers. Breakpo ... more

  • Companies

    Evotec Neurosciences GmbH

    Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more

    Evotec SE

    Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE